The surge of patent expiration of branded drugs is the most significant factor driving the growth for this market. Growing prevalence of chronic diseases,.
Data Bridge Market Research completed a qualitative study titled Generic Drug Market with 100+ market data tables, pie charts, graphs, and figures spread
A couple of years ago, in
Amerigen Pharmaceuticals Ltd. v. UCB Pharma
GmbH, 913 F.3d 1076, 1082 (Fed. Cir. 2019), the Federal
Circuit acknowledged its jurisdiction to decide appeals of the
Board s final written decisions in AIA trials, but explained
that an appellant (AIA Trial petitioner) must demonstrate it has
standing. Quoting from the Supreme Court s decision in
Spokeo, Inc. v. Robins, 136 S. Ct.
1540, 1547 (2016), the court explained the appellant must
demonstrate, among other things, that it has suffered an
injury in fact.
Amerigen, 913 F.3d at
1082–83. The court more recently explained that the appellant
who claims injury by the Board s decision need not face a
ANI Pharma Says FDA Approved And Launched Aminocaproic Acid Tablets
WASHINGTON (dpa-AFX) - Specialty pharmaceutical firm ANI Pharmaceuticals, Inc. (ANIP) announced Thursday that the U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg.
The current annual U.S. market for this product is approximately $12.7 million, according to IQVIA/IMS Health. This important therapeutic is one of the pipeline generic products ANI acquired from Amerigen Pharmaceuticals, Ltd. earlier this year.
Aminocaproic Acid tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.